Prostvac

Prostvac is an investigational immunotherapy for the treatment of prostate cancer. It is being developed by Bavarian Nordic, a biotechnology company specializing in vaccines.

Overview

Prostvac uses a virus as a vector to deliver antigens to the immune system. The antigens are designed to stimulate an immune response against prostate-specific antigen (PSA), a protein that is overexpressed in prostate cancer cells.

Clinical Trials

Prostvac has been tested in several clinical trials. In a Phase II trial, Prostvac was shown to extend the median survival of patients with metastatic castration-resistant prostate cancer by 8.5 months compared to a placebo. However, a subsequent Phase III trial did not meet its primary endpoint of improving overall survival.

Mechanism of Action

Prostvac works by stimulating the body's immune system to attack prostate cancer cells. It does this by using a virus to deliver antigens to the immune system. These antigens are designed to stimulate an immune response against prostate-specific antigen (PSA), a protein that is overexpressed in prostate cancer cells.

Side Effects

The most common side effects of Prostvac are flu-like symptoms, including fever, chills, and fatigue. These symptoms are typically mild and temporary.

See Also

• Immunotherapy
• Prostate cancer
• Clinical trial
• Antigen
• Prostate-specific antigen

Prostvac Resources
Latest articles Most recent articles Ongoing trials	Wikipedia